Drugs / CEA CAR-T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06010862 | Sep 2023 → Dec 2025 overdue | breast cancer, cholangiocarcinoma, colorectal cancer, esophageal cancer +3 | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT05415475 | Sep 2021 → Jun 2025 | colorectal cancer, esophageal cancer, gastric cancer, malignant pancreatic neoplasm +1 | Chongqing Precision Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04348643 | Feb 2020 → Dec 2023 | breast cancer, colorectal cancer, gastric cancer, liver cancer +2 | Chongqing Precision Biotech Co., Ltd | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEA CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06010862 ↗ |
| Action | Deplete | “CAR-T cell preparations have a certain killing effect on CEA-positive tumor cells” NCT05415475 ↗ |
| Modality | Cell therapy | “CEA-targeted CAR-T cells therapy” NCT04348643 ↗ |
| Route | Intravenous | “CEA-CAR-T cells will be administered intravenously.” NCT04348643 ↗ |